Project Grant R01HL173191
Award Date
12/16/24
Completion Date
11/30/28
Dollars Obligated
$784K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Bronx, NY 10461, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $785,198 to the Albert Einstein College of Medicine to study the role of chaperone-mediated autophagy (CMA) in regulating the function and phenotypic transitions of cardiac fibroblasts and myofibroblasts following myocardial infarction. The research aims to determine how CMA modulates the proteomic profile, phenotype, and function of reparative fibroblasts and...
This Project Grant award of $771,750 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at the University of California, Los Angeles (UCLA) to investigate the role of macrophages in regulating cardiac muscle metabolism after myocardial infarction. The key goals are to: Examine how macrophages recruited to the infarcted heart disrupt cardiac muscle metabolism and decrease NAD pools, which are critical for cardiac energetics....
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,510,312 to Albert Einstein College of Medicine to support research on ribosomal RNA modification in nucleoli and its relationship to inherited and somatic diseases. The research aims to elucidate how the dense fibrillar component of the nucleolus forms, the mechanism of co-transcriptional RNA modification, and the impact of dyskeratosis congenita. The award...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $161,922 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Albert Einstein College of Medicine. The grant, awarded on July 9, 2025, will fund research to elucidate the interplay between DDX41 and CUX1 mutations and their impact on hematopoiesis in zebrafish and human induced pluripotent stem cells. The project aims to provide mechanistic insights into how these co-occurring mutations contribute to the...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $500,089.80 to the University of Pittsburgh to investigate the role of macrophages in heart failure with preserved ejection fraction (HFPEF). The research aims to uncover the mechanisms by which inflammatory macrophages cause cardiac remodeling in HFPEF at the cellular, molecular, and functional levels. Specifically, the project will investigate how inflammatory...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA Program 93.837 Cardiovascular Diseases Research) provides $740,037 to the University of California, Los Angeles (UCLA) to investigate the role of cardiac fibroblasts in regulating angiogenesis following myocardial infarction. The key objectives are to evaluate the function of anti-angiogenic factors, such as collagen type XVIII, and determine if the expression of pro-angiogenic factors, such as slit guidance ligand...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $146,922 to the Albert Einstein College of Medicine to investigate the mechanisms driving hematopoietic stem and progenitor cell (HSPC) dysfunction associated with the inherited form of myelodysplastic syndrome (MDS). The research aims to decipher how environmental factors synergize with the DDX41 gene mutation to promote HSPC dysfunction, including the potential...
This Project Grant award of $252,854 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) supports research to develop computational tools that can link single-cell RNA sequencing (scRNAseq) data to experimentally-testable predictions about the functional consequences of different cardiomyocyte subtypes. The project combines scRNAseq, mechanistic mathematical modeling, and physiological assays to investigate how...
This Project Grant award of $2,352,138.00, provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research to model cell-specific signaling of the Low-Density Lipoprotein Receptor Related Protein-1 (LRP1) in acute myocardial infarction (AMI). The research aims to expand and experimentally validate signaling networks that predict how early cardiomyocyte LRP1 signaling enhances cell survival after ischemia-reperfusion, as well as how late...
This Project Grant award from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to understand the role of macrophages in preserving cardiovascular health and their contributions to cardiovascular disease (CVD). The $1,127,798 award to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), aims to define new therapeutic targets for female and male CVD patients. The research focuses on...